Symbol | Exchange | Currency | |||
|---|---|---|---|---|---|
| PFE | · | NYSE | · | USD | |
| PFE | · | Toronto | · | CAD | |
| PFE | · | CBOE Canada | · | CAD | |
| PFE | · | Mexico | · | MXN | |
| 1PFE | · | Milan | · | EUR | |
| PFECHF | · | Switzerland | · | CHF | |
| PFE | · | Hamburg | · | EUR | |
| PFE | · | Frankfurt | · | EUR | |
| PFE | · | Xetra | · | EUR | |
| PFE | · | TradeGate | · | EUR | |
| PFE | · | Santiago | · | USD | |
| PFEm | · | Buenos Aires | · | ARS | |
| PFIZ34 | · | B3 | · | BRL | |
| PFE | · | Vienna | · | EUR | |
| PFE | · | Ukraine | · | UAH | |
| PFE_KZ | · | KASE | · | USD | |
| PFE_KZTQBD | · | KASE | · | USD | |
| PFECO | · | Colombia | · | COP | |
| PFEUS | · | Lima | · | USD |
Strategic Transformation | Management pursues aggressive cost restructuring targeting over $7 billion in savings by 2027 while deploying COVID profits toward strategic acquisitions including anti-obesity market entry |
Clinical Innovation | Tukysa demonstrates breakthrough results in HER2-positive metastatic breast cancer with 13-month progression-free survival benefit, though liver safety concerns may limit adoption |
Analyst Perspectives | Average price target stands at $28, with BMO Capital's $30 target reflecting optimism about transformative acquisitions while Citi's $26 target weighs patent challenges |
Patent Cliff Ahead | Pfizer confronts revenue declines through 2026 as multiple products face patent expirations between 2026-2029, threatening billions in annual revenues amid intensifying generic competition |

Metrics to compare | PFE | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPFEPeersSector | |
|---|---|---|---|---|
P/E Ratio | 19.7x | 20.1x | −0.5x | |
PEG Ratio | −3.85 | 0.37 | 0.00 | |
Price / Book | 1.6x | 1.5x | 2.6x | |
Price / LTM Sales | 2.3x | 2.7x | 3.1x | |
Upside (Analyst Target) | 8.6% | 29.6% | 51.6% | |
Fair Value Upside | Unlock | 33.5% | 6.0% | Unlock |
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.